These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 3324051)

  • 1. Spasticity and drug therapy.
    Wuis EW
    Pharm Weekbl Sci; 1987 Oct; 9(5):249-60. PubMed ID: 3324051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Traditional pharmacological treatments for spasticity. Part II: General and regional treatments.
    Gracies JM; Nance P; Elovic E; McGuire J; Simpson DM
    Muscle Nerve Suppl; 1997; 6():S92-120. PubMed ID: 9826984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacotherapy of spasticity in children with cerebral palsy.
    Chung CY; Chen CL; Wong AM
    J Formos Med Assoc; 2011 Apr; 110(4):215-22. PubMed ID: 21540003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The physiology of spasticity and its response to therapy.
    Young RR
    Ann N Y Acad Sci; 1988; 531():146-9. PubMed ID: 3382140
    [No Abstract]   [Full Text] [Related]  

  • 5. [Antispastic treatment of paraplegic patients].
    Azouvi P; Roby-Brami A; Tougeron A; Bussel B
    Rev Prat; 1988 Oct; 38(25):1806-9. PubMed ID: 3194691
    [No Abstract]   [Full Text] [Related]  

  • 6. A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis.
    Smolenski C; Muff S; Smolenski-Kautz S
    Curr Med Res Opin; 1981; 7(6):374-83. PubMed ID: 7016449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spasticity: revisiting the role and the individual value of several pharmacological treatments.
    Lapeyre E; Kuks JB; Meijler WJ
    NeuroRehabilitation; 2010; 27(2):193-200. PubMed ID: 20871149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative profile of tizanidine in the management of spasticity.
    Lataste X; Emre M; Davis C; Groves L
    Neurology; 1994 Nov; 44(11 Suppl 9):S53-9. PubMed ID: 7970011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A benefit-risk assessment of baclofen in severe spinal spasticity.
    Dario A; Tomei G
    Drug Saf; 2004; 27(11):799-818. PubMed ID: 15350152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antispastic medication. A review.
    Mårtensson A
    Scand J Rehabil Med; 1981; 13(4):143-7. PubMed ID: 6750782
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug treatment of spasticity.
    Richens A
    Trans Med Soc Lond; 1975-1977; 92-93():127-30. PubMed ID: 1053111
    [No Abstract]   [Full Text] [Related]  

  • 12. The management of cerebral palsy: subjectivity and a conundrum.
    Bodensteiner JB
    J Child Neurol; 1996 Mar; 11(2):75-76. PubMed ID: 8881980
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost analysis of the treatment of severe spinal spasticity with a continuous intrathecal baclofen infusion system.
    Postma TJ; Oenema D; Terpstra S; Bouma J; Kuipers-Upmeijer H; Staal MJ; Middel BJ
    Pharmacoeconomics; 1999 Apr; 15(4):395-404. PubMed ID: 10537958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic and surgical therapy for spasticity.
    Tibbs PA; Young AB; Walsh JW; Bean JR
    J Ky Med Assoc; 1981 Jun; 79(6):359-62. PubMed ID: 7264443
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacotherapy of spasticity: some theoretical and practical considerations.
    Rice GP
    Can J Neurol Sci; 1987 Aug; 14(3 Suppl):510-2. PubMed ID: 3315153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Muscle relaxants in multiple sclerosis.
    Basmajian JV
    Int Disabil Stud; 1987; 9(2):90-1. PubMed ID: 3680109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological interventions for spasticity following spinal cord injury: results of a Cochrane systematic review.
    Taricco M; Pagliacci MC; Telaro E; Adone R
    Eura Medicophys; 2006 Mar; 42(1):5-15. PubMed ID: 16565680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis.
    Eyssette M; Rohmer F; Serratrice G; Warter JM; Boisson D
    Curr Med Res Opin; 1988; 10(10):699-708. PubMed ID: 3286128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug therapy: spasticity (first of two parts).
    Young RR; Delwaide PJ
    N Engl J Med; 1981 Jan; 304(1):28-33. PubMed ID: 6448959
    [No Abstract]   [Full Text] [Related]  

  • 20. The treatment of spasticity in multiple sclerosis: a double-blind clinical trial of a new anti-spastic drug tizanidine compared with baclofen.
    Stien R; Nordal HJ; Oftedal SI; Slettebø M
    Acta Neurol Scand; 1987 Mar; 75(3):190-4. PubMed ID: 3554879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.